Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

alpha-galactosidase A from human placenta. Stability and subunit size

J S Mayes, E Beutler

    Biochimica Et Biophysica Acta
    |October 13, 1977
    PubMed
    Summary

    Purified human placental alpha-galactosidase A is a heat-labile dimer, unstable in plasma. Its instability presents a significant challenge for treating Fabry

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    1342C mutation in Gaucher's disease.

    Lancet (London, England)·1995
    Same author

    Triosephosphate isomerase deficiency: repetitive occurrence of point mutation in amino acid 104 in multiple apparently unrelated families.

    American journal of hematology·1995
    Same author

    Gaucher disease.

    Medicine·1995
    Same author

    Treatment regimens in Gaucher's disease.

    Lancet (London, England)·1995
    Same author

    Molecular study of pyruvate kinase deficient patients with hereditary nonspherocytic hemolytic anemia.

    The Journal of clinical investigation·1995
    Same author

    Erythrocyte fragility and chronic intermittent pigmenturia in a dog.

    Journal of the American Veterinary Medical Association·1995

    Area of Science:

    • Biochemistry
    • Enzymology
    • Human Genetics

    Background:

    • Alpha-galactosidase A (alpha-D-galactoside galactohydrolase, EC 3.2.1.22) is crucial for cellular function.
    • Fabry's disease is a genetic disorder linked to alpha-galactosidase A deficiency.

    Purpose of the Study:

    • To purify and characterize alpha-galactosidase A from human placenta.
    • To assess the enzyme's properties relevant to potential therapeutic applications.

    Main Methods:

    • Enzyme purification from human placenta.
    • Polyacrylamide gel electrophoresis (PAGE) and SDS-PAGE for molecular weight determination.
    • Double immunodiffusion for purity assessment.
    • Antibody production and precipitation assays.
    • Enzyme stability assays (heat, pH, plasma half-life).

    Main Results:

    • Purified enzyme exhibited a single major band on PAGE and immunodiffusion, indicating high purity.
    • SDS-PAGE revealed a dimer structure with subunits of approximately 67,500 Da, and a potential degradation product of 47,000 Da.
    • Antibodies specifically precipitated human placental alpha-galactosidase A, not the deficient form in Fabry's disease fibroblasts.
    • The enzyme is highly heat labile and pH sensitive, with optimal stability at pH 5.0-6.0.
    • In plasma at 37°C, alpha-galactosidase A has a short half-life of 17 minutes.

    Conclusions:

    • Human placental alpha-galactosidase A is a dimeric protein with specific antigenic properties.
    • The enzyme's inherent instability, particularly its rapid degradation in plasma, poses a significant obstacle for its therapeutic use in Fabry's disease.
    • Further research is needed to enhance enzyme stability for effective Fabry's disease treatment.

    Related Experiment Videos